Regulatory T cells in inflamed liver are dysfunctional in murine primary biliary cholangitis
Clinical and Experimental Immunology · 19.02.2024 · 215 (3) · 225-239
DOI: 10.1093/cei/uxad117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 31.10.2023. Verfasst von Chia-I Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary, Cholangitis, Autoimmune Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Health Research Institutes, Ministry of Science and Technology, Taiwan, National Taiwan University.
Abstract (Originalsprache)
Primary biliary cholangitis (PBC) is a chronic autoimmune disease characterized by immune-mediated destruction of intrahepatic small bile ducts. CD8 T cells play a critical role in biliary destruction. However, regulatory T cells (Tregs) have also been identified in the portal tracts of PBC patients. This study tested the hypothesis that hepatic Tregs in PBC were dysfunctional in suppressing immune responses in disease by using our human PBC-like autoimmune cholangitis (AIC) mouse model induced by 2-octynoic acid-conjugated ovalbumin (2-OA-OVA). Our results showed that female and male mice immunized with 2-OA-OVA developed AIC; however, female AIC mice had more severe liver inflammation and fibrosis than male AIC mice. Levels of functional effector CD8 T cells and their chemoattractants, CXCL9 and CXCL10, in the liver were markedly elevated in female AIC mice than in male AIC mice. These results reinforce that CD8 T cells are the primary effector cells in PBC. The number of hepatic Tregs in AIC mice was also higher than in saline-treated mice, but there was no difference between male and female AIC mice. The suppressive function of AIC Tregs was evident despite a discrepancy in the changes in their co-inhibitory receptors and inhibitory cytokines. However, the expansion of hepatic Tregs by low-dose IL-2 treatment did not reduce immune responses to AIC, which may be due to the dysfunction of Tregs in inhibiting T cells. In conclusion, the function of Tregs in the inflamed liver of PBC was insufficient, and low-dose IL-2 treatment could not restore their function to suppress pathological immune responses. Transferring normal Tregs or directly targeting effector CD8 T cells may be beneficial for treating PBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
- School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
ORCID-Profile: Ya-Hui Chuang
Förderung
- National Health Research Institutes
- Ministry of Science and Technology, Taiwan
- National Taiwan University
- National Taiwan University Hospital
Zitieren
APA
Lin, C. I., Wang, Y. W., Liu, C. Y., Chen, H. W., Liang, P. H., & Chuang, Y. H. (2024). Regulatory T cells in inflamed liver are dysfunctional in murine primary biliary cholangitis. Clinical and Experimental Immunology, 215(3), 225-239. https://doi.org/10.1093/cei/uxad117
Vancouver
Lin CI, Wang YW, Liu CY, Chen HW, Liang PH, Chuang YH. Regulatory T cells in inflamed liver are dysfunctional in murine primary biliary cholangitis. Clinical and Experimental Immunology. 2024;215(3):225-239. doi:10.1093/cei/uxad117
BibTeX
@article{Lin2024,
author = {Lin, Chia-I and Wang, Yu-Wen and Liu, Chih-Yu and Chen, Hung-Wen and Liang, Pi-Hui and Chuang, Ya-Hui},
title = {Regulatory T cells in inflamed liver are dysfunctional in murine primary biliary cholangitis},
journal = {Clinical and Experimental Immunology},
year = {2024},
volume = {215},
number = {3},
pages = {225--239},
doi = {10.1093/cei/uxad117}
}
EUVIMED